spironolactone has been researched along with Alopecia in 52 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Alopecia: Absence of hair from areas where it is normally present.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Topical minoxidil 5% are effective in androgenetic alopecia (AGA)." | 9.41 | A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: Clinical, histopathological, and physicochemical study. ( Abdel-Aziz, RTA; Abdel-Raouf, H; Ahmed, SS; Aly, UF; Medhat, W, 2021) |
| "To provide dermatologists and oncologists with a foundation for practical understanding and uses of 5α-reductase inhibitors and spironolactone for breast cancer patients and survivors receiving endocrine therapies (ETs), including the effect of these treatments on sex hormone levels, any reported drug interactions, and any risk of malignancy." | 9.01 | Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies. ( Freites-Martinez, A; Geer, EB; Goldfarb, S; Lacouture, ME; Rozner, RN; Shapiro, J, 2019) |
| "Spironolactone was not independently associated with increased BC recurrence and may be considered for the treatment of alopecia in BC survivors." | 7.96 | Spironolactone use does not increase the risk of female breast cancer recurrence: A retrospective analysis. ( Bovonratwet, P; Friedman, AJ; Gu, A; Moawad, G; Silverberg, JI; Wei, C, 2020) |
| "To analyze the clinical and histological features of permanent alopecia following a sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel regimen for adjuvant breast cancer treatment." | 7.78 | Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. ( Bessis, D; Dereure, O; Frouin, E; Guillot, B; Jacot, W; Kluger, N; Poujol, S; Rigau, V; Romieu, G, 2012) |
| " He developed nonA-nonB-induced liver cirrhosis and had been treated with spironolactone for the last 6 years." | 7.68 | Reversal of andro-genetic alopecia in a male. A spironolactone effect? ( Bou-Abboud, CF; Nemec, F; Toffel, F, 1990) |
| "Spironolactone is a synthetic aldosterone receptor antagonist, with a role off-label in various dermatological conditions." | 6.66 | Spironolactone in dermatology: uses in acne and beyond. ( Al-Niaimi, F; Ali, FR; Searle, TN, 2020) |
| "Both spironolactone as a 5% topical solution and minoxidil as a 5% topical solution might be used safely in a twice-daily dosage to treat AGA in both genders." | 5.72 | Dermoscopic evaluation of the efficacy of combination of topical spironolactone 5% and minoxidil 5% solutions in the treatment of androgenetic alopecia: A cross sectional-comparative study. ( Abdel-Dayem, HA; Ammar, AM; Elsaie, ML; Elshahid, AR; Mohamed, AA, 2022) |
| " We discuss the indications for spironolactone, dosing in dermatology, precautions to consider, and adverse effects." | 5.56 | Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Baldness, and Hirsutism. ( Morgado-Carrasco, D; Vargas-Mora, P, 2020) |
| "Topical minoxidil 5% are effective in androgenetic alopecia (AGA)." | 5.41 | A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: Clinical, histopathological, and physicochemical study. ( Abdel-Aziz, RTA; Abdel-Raouf, H; Ahmed, SS; Aly, UF; Medhat, W, 2021) |
| "Spironolactone (SL) is a US Food and Drug Administration-approved drug for the treatment of hypertension and various edematous conditions." | 5.40 | Follicular delivery of spironolactone via nanostructured lipid carriers for management of alopecia. ( Aburahma, MH; Shamma, RN, 2014) |
| "To provide dermatologists and oncologists with a foundation for practical understanding and uses of 5α-reductase inhibitors and spironolactone for breast cancer patients and survivors receiving endocrine therapies (ETs), including the effect of these treatments on sex hormone levels, any reported drug interactions, and any risk of malignancy." | 5.01 | Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies. ( Freites-Martinez, A; Geer, EB; Goldfarb, S; Lacouture, ME; Rozner, RN; Shapiro, J, 2019) |
| "Spironolactone was not independently associated with increased BC recurrence and may be considered for the treatment of alopecia in BC survivors." | 3.96 | Spironolactone use does not increase the risk of female breast cancer recurrence: A retrospective analysis. ( Bovonratwet, P; Friedman, AJ; Gu, A; Moawad, G; Silverberg, JI; Wei, C, 2020) |
| "To analyze the clinical and histological features of permanent alopecia following a sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel regimen for adjuvant breast cancer treatment." | 3.78 | Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. ( Bessis, D; Dereure, O; Frouin, E; Guillot, B; Jacot, W; Kluger, N; Poujol, S; Rigau, V; Romieu, G, 2012) |
| "A 53-year-old woman with clinical evidence of female pattern hair loss and histological evidence of androgenetic alopecia was initially treated with the oral antiandrogen spironolactone 200 mg daily." | 3.74 | Treatment of female pattern hair loss with a combination of spironolactone and minoxidil. ( Hoedemaker, C; Sinclair, R; van Egmond, S, 2007) |
| " He developed nonA-nonB-induced liver cirrhosis and had been treated with spironolactone for the last 6 years." | 3.68 | Reversal of andro-genetic alopecia in a male. A spironolactone effect? ( Bou-Abboud, CF; Nemec, F; Toffel, F, 1990) |
| "Patterned hair loss is a common type of non-scarring alopecia, characterized by miniaturization of hair follicles." | 3.01 | Combination therapy in female pattern hair loss. ( Deoghare, S; Sadick, NS, 2023) |
| "Thus, in patients with cancer, alopecia can be iatrogenic (chemotherapies, endocrine therapies, targeted therapies, immunotherapies, radiotherapy, surgery) or directly the consequence of the disease itself (malnutrition, scalp metastases, paraneoplastic syndromes)." | 2.72 | [Alopecia and cancers: From basics to clinical practice]. ( Baussard, L; Fiteni, F; Guichard, A; Le Vigouroux, S; Quesada, S, 2021) |
| "Spironolactone is a synthetic aldosterone receptor antagonist, with a role off-label in various dermatological conditions." | 2.66 | Spironolactone in dermatology: uses in acne and beyond. ( Al-Niaimi, F; Ali, FR; Searle, TN, 2020) |
| "(i) The term "female pattern hair loss" should be used, avoiding the previous terms of alopecia or androgenetic alopecia." | 2.61 | Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. ( Azziz, R; Bergfeld, W; Carmina, E; Escobar-Morreale, HF; Futterweit, W; Huddleston, H; Lobo, R; Olsen, E, 2019) |
| "Common types of nonscarring hair loss, including female pattern hair loss and telogen effluvium, may be diagnosed and managed by the obstetrician/gynecologist." | 2.52 | Hair loss in women. ( Bechtel, MA; Harfmann, KL, 2015) |
| "Female pattern hair loss, or female pattern androgenetic alopecia, is a nonscarring alopecia with a multi-factorial etiology that mostly affects postmenopausal women and is characterized by a reduction in hair density over the crown and frontal scalp." | 2.52 | Female pattern hair loss. ( Ioannides, D; Lazaridou, E, 2015) |
| "Flutamide was found to be more effective than spironolactone or cyproterone in one study." | 2.44 | A review of hormonal therapy for female pattern (androgenic) alopecia. ( Scheinfeld, N, 2008) |
| "Hair loss is a common complaint in the outpatient setting." | 2.42 | Hair loss remedies--separating fact from fiction. ( Bandaranayake, I; Mirmirani, P, 2004) |
| "Common baldness or androgenetic alopecia is a normal physiological process of hair loss in genetically predisposed individuals." | 2.40 | Understanding and managing common baldness. ( Sinclair, RD; Tran, D, 1999) |
| "Although hirsutism and androgenetic alopecia are cosmetic problems, they can be psychologically devastating for women." | 2.40 | Antiandrogen treatment of polycystic ovary syndrome. ( Rittmaster, RS, 1999) |
| "Androgenetic alopecia is an androgen dependent disorder occurring in genetically susceptible individuals." | 2.39 | Female androgenetic alopecia: an update. ( Callan, AW; Montalto, J, 1995) |
| "Both spironolactone as a 5% topical solution and minoxidil as a 5% topical solution might be used safely in a twice-daily dosage to treat AGA in both genders." | 1.72 | Dermoscopic evaluation of the efficacy of combination of topical spironolactone 5% and minoxidil 5% solutions in the treatment of androgenetic alopecia: A cross sectional-comparative study. ( Abdel-Dayem, HA; Ammar, AM; Elsaie, ML; Elshahid, AR; Mohamed, AA, 2022) |
| " We discuss the indications for spironolactone, dosing in dermatology, precautions to consider, and adverse effects." | 1.56 | Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Baldness, and Hirsutism. ( Morgado-Carrasco, D; Vargas-Mora, P, 2020) |
| "Diffuse alopecia was predominant in patients with pCIA compared with patients with EIAC (31 of 75 [41%] vs 23 of 92 [25%]; P = ." | 1.51 | Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia. ( Chan, D; Cho, J; Cigler, T; Fabbrocini, G; Freites-Martinez, A; Gajria, D; Goldfarb, S; Lacouture, ME; Modi, S; Norton, L; Paus, R; Shapiro, J; Sibaud, V; Tosti, A, 2019) |
| "Mean hair loss severity at baseline was Sinclair 2." | 1.48 | Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. ( Sinclair, RD, 2018) |
| "Female pattern hair loss (FPHL) is a commonly encountered clinical presentation in primary care." | 1.48 | Female pattern hair loss. ( Chan, L; Cook, DK, 2018) |
| "Spironolactone (SL) is a US Food and Drug Administration-approved drug for the treatment of hypertension and various edematous conditions." | 1.40 | Follicular delivery of spironolactone via nanostructured lipid carriers for management of alopecia. ( Aburahma, MH; Shamma, RN, 2014) |
| "Female pattern hair loss is a common but difficult to manage condition." | 1.37 | Treatment of female pattern hair loss with the androgen receptor antagonist flutamide. ( Sinclair, R; Yazdabadi, A, 2011) |
| "Spironolactone is a synthetic steroid structurally related to aldosterone." | 1.36 | Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. ( Rathnayake, D; Sinclair, R, 2010) |
| " We investigated the dose-response relationship for suppression of dehydroepiandrosterone sulfate (DHEAS) with the use of dexamethasone." | 1.28 | Treatment of androgenic disorders with dexamethasone: dose-response relationship for suppression of dehydroepiandrosterone sulfate. ( Bedocs, NM; Bergfeld, W; Gidwani, GP; Gupta, MK; Parker, R; Redmond, GP; Skibinski, C, 1990) |
| " In 11 women (68%), the dosage had to be decreased or the medication discontinued due to side-effects." | 1.27 | Side-effects of spironolactone therapy in the hirsute woman. ( Helfer, EL; Miller, JL; Rose, LI, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (7.69) | 18.7374 |
| 1990's | 9 (17.31) | 18.2507 |
| 2000's | 11 (21.15) | 29.6817 |
| 2010's | 17 (32.69) | 24.3611 |
| 2020's | 11 (21.15) | 2.80 |
| Authors | Studies |
|---|---|
| Ammar, AM | 1 |
| Elshahid, AR | 1 |
| Abdel-Dayem, HA | 1 |
| Mohamed, AA | 1 |
| Elsaie, ML | 1 |
| Collins, MS | 1 |
| Ali, S | 1 |
| Wiss, IP | 1 |
| Senna, MM | 2 |
| Deoghare, S | 1 |
| Sadick, NS | 1 |
| Burns, LJ | 1 |
| De Souza, B | 1 |
| Flynn, E | 1 |
| Hagigeorges, D | 1 |
| Wei, C | 1 |
| Bovonratwet, P | 1 |
| Gu, A | 1 |
| Moawad, G | 1 |
| Silverberg, JI | 1 |
| Friedman, AJ | 1 |
| Vargas-Mora, P | 1 |
| Morgado-Carrasco, D | 1 |
| Searle, TN | 1 |
| Al-Niaimi, F | 1 |
| Ali, FR | 1 |
| Abdel-Raouf, H | 1 |
| Aly, UF | 1 |
| Medhat, W | 1 |
| Ahmed, SS | 1 |
| Abdel-Aziz, RTA | 1 |
| Olamiju, B | 1 |
| Craiglow, BG | 1 |
| Quesada, S | 1 |
| Guichard, A | 1 |
| Le Vigouroux, S | 1 |
| Baussard, L | 1 |
| Fiteni, F | 1 |
| James, JF | 1 |
| Jamerson, TA | 1 |
| Aguh, C | 1 |
| Rodrigues, M | 1 |
| Antunes, I | 1 |
| Magalhães, S | 1 |
| Pereira, N | 1 |
| Sinclair, RD | 3 |
| Chan, L | 1 |
| Cook, DK | 1 |
| Azarchi, S | 1 |
| Bienenfeld, A | 1 |
| Lo Sicco, K | 1 |
| Marchbein, S | 1 |
| Shapiro, J | 5 |
| Nagler, AR | 1 |
| Rozner, RN | 1 |
| Freites-Martinez, A | 2 |
| Geer, EB | 1 |
| Goldfarb, S | 2 |
| Lacouture, ME | 2 |
| Carmina, E | 1 |
| Azziz, R | 1 |
| Bergfeld, W | 3 |
| Escobar-Morreale, HF | 1 |
| Futterweit, W | 1 |
| Huddleston, H | 1 |
| Lobo, R | 1 |
| Olsen, E | 1 |
| Chan, D | 1 |
| Sibaud, V | 1 |
| Fabbrocini, G | 1 |
| Tosti, A | 1 |
| Cho, J | 1 |
| Modi, S | 1 |
| Gajria, D | 1 |
| Norton, L | 1 |
| Paus, R | 1 |
| Cigler, T | 1 |
| Buzney, E | 1 |
| Sheu, J | 1 |
| Buzney, C | 1 |
| Reynolds, RV | 1 |
| Shamma, RN | 1 |
| Aburahma, MH | 1 |
| Harfmann, KL | 1 |
| Bechtel, MA | 1 |
| Famenini, S | 1 |
| Slaught, C | 1 |
| Duan, L | 1 |
| Goh, C | 1 |
| Ioannides, D | 1 |
| Lazaridou, E | 1 |
| Vary, JC | 1 |
| Scheinfeld, N | 1 |
| Yazdabadi, A | 2 |
| Green, J | 1 |
| Sinclair, R | 5 |
| Rathnayake, D | 1 |
| Kluger, N | 1 |
| Jacot, W | 1 |
| Frouin, E | 1 |
| Rigau, V | 1 |
| Poujol, S | 1 |
| Dereure, O | 1 |
| Guillot, B | 1 |
| Romieu, G | 1 |
| Bessis, D | 1 |
| Adenuga, P | 1 |
| Summers, P | 1 |
| Bandaranayake, I | 1 |
| Mirmirani, P | 1 |
| Olsen, EA | 2 |
| Messenger, AG | 1 |
| Bergfeld, WF | 1 |
| Hordinsky, MK | 1 |
| Roberts, JL | 1 |
| Stough, D | 1 |
| Washenik, K | 1 |
| Whiting, DA | 1 |
| Wewerinke, M | 1 |
| Jolley, D | 1 |
| Hannuksela, M | 2 |
| Hoedemaker, C | 1 |
| van Egmond, S | 1 |
| Zaun, H | 1 |
| Belaube, P | 1 |
| Devaux, J | 1 |
| Gamby, T | 1 |
| Garcin, G | 1 |
| Privat, Y | 1 |
| Callan, AW | 1 |
| Montalto, J | 1 |
| Aguirre, A | 1 |
| Manzano, D | 1 |
| Zabala, R | 1 |
| Eizaguirre, X | 1 |
| Díaz-Pérez, JL | 1 |
| Fernandez-Vozmediano, JM | 1 |
| Gil-Tocados, G | 1 |
| Manrique-Plaza, A | 1 |
| Romero-Cabrera, MA | 1 |
| Picazo-Sanchez, J | 1 |
| Nieto-Montesinos, I | 1 |
| Adamopoulos, DA | 1 |
| Karamertzanis, M | 1 |
| Nicopoulou, S | 1 |
| Gregoriou, A | 1 |
| Price, VH | 1 |
| Tran, D | 1 |
| Rittmaster, RS | 1 |
| Thai, KE | 1 |
| Bou-Abboud, CF | 1 |
| Nemec, F | 1 |
| Toffel, F | 1 |
| Redmond, GP | 1 |
| Gidwani, GP | 1 |
| Gupta, MK | 1 |
| Bedocs, NM | 1 |
| Parker, R | 1 |
| Skibinski, C | 1 |
| Burke, BM | 1 |
| Cunliffe, WJ | 1 |
| Helfer, EL | 1 |
| Miller, JL | 1 |
| Rose, LI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| International Phase III, Multi Center, Randomized, Double Blind, Placebo and Active Controlled and Parallel Group Clinical Trial to Evaluate the Efficacy and Safety of Oral Minoxidil 1 mg in Female Patients With Androgenetic Alopecia[NCT05888922] | Phase 3 | 520 participants (Anticipated) | Interventional | 2024-03-31 | Not yet recruiting | ||
| Evaluating PAI-1 Expression in the Hair Follicles of Patients With Non-scarring Hair Loss.[NCT02548689] | 10 participants (Actual) | Observational | 2015-07-31 | Terminated (stopped due to Original lead investigator left Northwestern University) | |||
| A Randomized Controlled Trial to Evaluate Effectiveness of Cooling Cap to Prevent Permanent Chemotherapy-induced Alopecia Among Breast Cancer Patients[NCT04678544] | 170 participants (Actual) | Interventional | 2020-12-23 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
19 reviews available for spironolactone and Alopecia
| Article | Year |
|---|---|
Combination therapy in female pattern hair loss.
Topics: Alopecia; Combined Modality Therapy; Female; Finasteride; Humans; Minoxidil; Spironolactone; Treatme | 2023 |
Spironolactone in dermatology: uses in acne and beyond.
Topics: Acne Vulgaris; Adult; Alopecia; Dermatology; Drug Monitoring; Female; Hidradenitis Suppurativa; Hirs | 2020 |
[Alopecia and cancers: From basics to clinical practice].
Topics: Alopecia; Antihypertensive Agents; Antineoplastic Agents; Bimatoprost; Hair; Hair Follicle; Humans; | 2021 |
Efficacy and safety profile of oral spironolactone use for androgenic alopecia: A systematic review.
Topics: Administration, Oral; Alopecia; Hair; Humans; Spironolactone | 2022 |
Androgens in women: Hormone-modulating therapies for skin disease.
Topics: 5-alpha Reductase Inhibitors; Acne Vulgaris; Adrenal Hyperplasia, Congenital; Alopecia; Androgen Ant | 2019 |
Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Antineoplastic Agents; Breast Neoplasms; Female; Finasteride | 2019 |
Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Androgen Antagonists; Female; Humans; Hyperandrogenism; Low- | 2019 |
Polycystic ovary syndrome: a review for dermatologists: Part II. Treatment.
Topics: 5-alpha Reductase Inhibitors; Acne Vulgaris; Alopecia; Androgen Antagonists; Contraceptives, Oral, C | 2014 |
Hair loss in women.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Androgen Antagonists; Female; Finasteride; Flutamide; Hair; | 2015 |
Female pattern hair loss.
Topics: 5-alpha Reductase Inhibitors; Administration, Cutaneous; Alopecia; Androgen Antagonists; Androgen Re | 2015 |
Selected Disorders of Skin Appendages--Acne, Alopecia, Hyperhidrosis.
Topics: Acetylcholine Release Inhibitors; Acne Vulgaris; Algorithms; Alopecia; Anti-Bacterial Agents; Antipe | 2015 |
A review of hormonal therapy for female pattern (androgenic) alopecia.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Androgen Antagonists; Androgens; Cyproterone Acetate; Dermat | 2008 |
Hair loss remedies--separating fact from fiction.
Topics: Alopecia; Azasteroids; Dietary Supplements; Dutasteride; Enzyme Inhibitors; Female; Finasteride; Hum | 2004 |
[The treatment of female pattern hair loss].
Topics: Administration, Oral; Administration, Topical; Adult; Age Distribution; Alopecia; Female; Finland; F | 2006 |
Female androgenetic alopecia: an update.
Topics: Alopecia; Androgens; Cyproterone Acetate; Female; Humans; Minoxidil; Prognosis; Spironolactone | 1995 |
Hair regrowth. Therapeutic agents.
Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Alopecia; Alopecia Areata; Androgen Antagon | 1998 |
Understanding and managing common baldness.
Topics: Alopecia; Androgen Antagonists; Cyproterone Acetate; Female; Finasteride; Hair; Humans; Incidence; M | 1999 |
Antiandrogen treatment of polycystic ovary syndrome.
Topics: Alopecia; Androgen Antagonists; Androgens; Cyproterone Acetate; Female; Finasteride; Flutamide; Hirs | 1999 |
[Loss of hair].
Topics: Alopecia; Androgen Antagonists; Cyproterone Acetate; Enzyme Inhibitors; Female; Finasteride; Hair; H | 2000 |
2 trials available for spironolactone and Alopecia
| Article | Year |
|---|---|
A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: Clinical, histopathological, and physicochemical study.
Topics: Administration, Topical; Alopecia; Drug Therapy, Combination; Hair; Humans; Minoxidil; Scalp; Spiron | 2021 |
Treatment of female pattern hair loss with oral antiandrogens.
Topics: Adolescent; Adult; Aged; Alopecia; Androgen Antagonists; Biopsy; Child; Cyproterone Acetate; Female; | 2005 |
31 other studies available for spironolactone and Alopecia
| Article | Year |
|---|---|
Dermoscopic evaluation of the efficacy of combination of topical spironolactone 5% and minoxidil 5% solutions in the treatment of androgenetic alopecia: A cross sectional-comparative study.
Topics: Administration, Topical; Alopecia; Cross-Sectional Studies; Double-Blind Method; Female; Humans; Mal | 2022 |
Retrospective analysis of the risk of hyperkalaemia in women older than 65 years of age prescribed spironolactone for female-pattern hair loss.
Topics: Alopecia; Drug Therapy, Combination; Female; Humans; Hyperkalemia; Retrospective Studies; Spironolac | 2023 |
Spironolactone for treatment of female pattern hair loss.
Topics: Adult; Aged; Alopecia; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Human | 2020 |
Spironolactone use does not increase the risk of female breast cancer recurrence: A retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Breast Neoplasms; Databases, Factual; Female; Humans; Midd | 2020 |
Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Baldness, and Hirsutism.
Topics: Acne Vulgaris; Alopecia; Dermatology; Female; Hidradenitis Suppurativa; Hirsutism; Humans; Spironola | 2020 |
Combination oral minoxidil and spironolactone for the treatment of androgenetic alopecia in adolescent girls.
Topics: Administration, Oral; Adolescent; Alopecia; Dermoscopy; Drug Therapy, Combination; Female; Hair Foll | 2021 |
Androgenic alopecia: an entity to consider in adolescence.
Topics: Adolescent; Alopecia; Contraceptives, Oral, Hormonal; Female; Humans; Mineralocorticoid Receptor Ant | 2017 |
Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Diuretics; Drug Combinat | 2018 |
Female pattern hair loss.
Topics: 5-alpha Reductase Inhibitors; Adult; Alopecia; Androgen Receptor Antagonists; Female; Humans; Minoxi | 2018 |
Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents | 2019 |
Follicular delivery of spironolactone via nanostructured lipid carriers for management of alopecia.
Topics: Alopecia; Animals; Drug Carriers; Hair Follicle; Lipids; Mice; Models, Chemical; Nanostructures; Rho | 2014 |
Demographics of women with female pattern hair loss and the effectiveness of spironolactone therapy.
Topics: Aged; Alopecia; Cohort Studies; Demography; Female; Follow-Up Studies; Humans; Incidence; Middle Age | 2015 |
Successful treatment of female-pattern hair loss with spironolactone in a 9-year-old girl.
Topics: Administration, Oral; Alopecia; Child; Female; Humans; Mineralocorticoid Receptor Antagonists; Spiro | 2009 |
Treating female pattern hair loss. Noticeable hair loss can be deeply distressing. Here are some medical treatments that may help.
Topics: Administration, Cutaneous; Administration, Oral; Alopecia; Androgen Antagonists; Female; Hair; Healt | 2009 |
Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss.
Topics: Adolescent; Adult; Alopecia; Androgen Antagonists; Female; Humans; Male; Middle Aged; Minoxidil; Off | 2010 |
Treatment of female pattern hair loss with the androgen receptor antagonist flutamide.
Topics: Adult; Alopecia; Androgen Receptor Antagonists; Drug Therapy, Combination; Female; Flutamide; Hair; | 2011 |
Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast | 2012 |
Hair regrowth in a male patient with extensive androgenetic alopecia on estrogen therapy.
Topics: Administration, Cutaneous; Adult; Alopecia; Drug Therapy, Combination; Estradiol; Estrogens; Humans; | 2012 |
Evaluation and treatment of male and female pattern hair loss.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Administration, Topical; Adoles | 2005 |
Treatment of female pattern hair loss with a combination of spironolactone and minoxidil.
Topics: Administration, Cutaneous; Administration, Oral; Alopecia; Drug Therapy, Combination; Female; Humans | 2007 |
[Indications and limits of anti-androgen therapy].
Topics: Acne Vulgaris; Alopecia; Androgen Antagonists; Chlormadinone Acetate; Cyproterone; Cyproterone Aceta | 1984 |
[Hormonotherapy in acute, idiopathic hirsutism, and seborrheic alopecia (author's transl)].
Topics: Acne Vulgaris; Alopecia; Androgen Antagonists; Androgens; Cyproterone; Dermatitis, Seborrheic; Estro | 1982 |
Allergic contact dermatitis from spironolactone.
Topics: Adult; Alopecia; Dermatitis, Allergic Contact; Drug Eruptions; Female; Humans; Scalp Dermatoses; Spi | 1994 |
Contact dermatitis due to topical spironolactone.
Topics: Administration, Topical; Adult; Alopecia; Dermatitis, Allergic Contact; Dermatitis, Seborrheic; Drug | 1994 |
Beneficial effect of spironolactone on androgenic alopecia.
Topics: Adolescent; Adult; Alopecia; Evaluation Studies as Topic; Female; Humans; Male; Mineralocorticoid Re | 1997 |
Spironolactone-induced hepatitis.
Topics: Alopecia; Chemical and Drug Induced Liver Injury; Female; Humans; Liver Function Tests; Middle Aged; | 2001 |
My hair is thinning on the top of my head. What treatments are available for hair loss in women?
Topics: Alopecia; Diuretics; Enzyme Inhibitors; Female; Finasteride; Humans; Minoxidil; Spironolactone; Unit | 2002 |
Reversal of andro-genetic alopecia in a male. A spironolactone effect?
Topics: Aged; Alopecia; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hair; Humans; Liver Cir | 1990 |
Treatment of androgenic disorders with dexamethasone: dose-response relationship for suppression of dehydroepiandrosterone sulfate.
Topics: Acne Vulgaris; Adolescent; Adult; Alopecia; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; | 1990 |
Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia.
Topics: Acne Vulgaris; Alopecia; Androgen Antagonists; Female; Hirsutism; Humans; Spironolactone | 1985 |
Side-effects of spironolactone therapy in the hirsute woman.
Topics: Adult; Alopecia; Female; Hirsutism; Humans; Menstrual Cycle; Metrorrhagia; Spironolactone; Testoster | 1988 |